Work Group, Christopher Bichakjian, April Armstrong, Christian Baum, Jeremy S. Bordeaux, Marc Brown, Klaus J. Busam, Daniel B. Eisen, Vivek Iyengar, Clifford Lober, David J. Margolis, Jane Messina, Alexander Miller, Stanley Miller, Eliot Mostow, Christen Mowad, Kishwer Nehal, Kristi Schmitt-Burr, Aleksandar Sekulic, Paul Storrs, Joyce Teng, Siegrid Yu, Conway Huang, Kevin Boyer, Wendy Smith Begolka, Murad Alam, Invited Reviewers, John Y.S. Kim, Jeffrey H. Kozlow, Bharat Mittal, Jeffrey Moyer, Thomas Olencki, Phillip Rodgers

Basal cell carcinoma (BCC) is the most common form of human cancer, with a continually increasing annual incidence in the United States. When diagnosed early, the majority of BCCs are readily treated with office-based therapy, which is highly curative. In these evidence-based guidelines of care, we provide recommendations for the management of patients with BCC, as well as an in-depth review of the best available literature in support of these recommendations. We discuss biopsy techniques for a clinically suspicious lesion and offer recommendations for the histopathologic interpretation of BCC. In the absence of a formal staging system, the best available stratification based on risk for recurrence is reviewed. With regard to treatment, we provide recommendations on treatment modalities along a broad therapeutic spectrum, ranging from topical agents and superficially destructive modalities to surgical techniques and systemic therapy. Finally, we review the available literature and provide recommendations on prevention and the most appropriate follow-up for patients in whom BCC has been diagnosed.